Product/Composition:- | Calcium Dobesilate Tablets & Capsules |
---|---|
Strength:- | 250 mg & 500 mg |
Form:- | Tablets & Capsules |
Reference Brands:- | Doxium®, Doxium MADAUS® (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Calcium Dobesilate improves microcirculation by reducing capillary permeability and enhancing vascular resistance. It stabilizes endothelial function, inhibits platelet aggregation, and decreases blood viscosity. Clinically, it benefits patients with diabetic retinopathy, chronic venous insufficiency, and hemorrhoids by improving blood flow, reducing edema, and preventing microvascular complications in chronic vascular conditions.
Calcium Dobesilate is primarily approved and marketed in the European Union and several other countries but is not FDA-approved in the United States. It is widely prescribed in the EU under brand names like Doxium® for the treatment of chronic venous insufficiency, diabetic retinopathy, and hemorrhoidal disease. The drug is classified as a vasoprotective agent with angioprotective and anti-inflammatory effects. Regulatory bodies in the EU consider it safe and effective when prescribed appropriately, although it is not included in U.S. pharmacotherapy due to lack of FDA approval. Physicians in the EU continue to favor it for vascular and retinal microcirculation support.